You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com
Hepatitis C FDA-Approved Combination Therapy
Boceprevir + Pegylated Interferon + Ribavirin Telaprevir+ Pegylated Interferon + Ribavirin Pegasys + Copegus (peginterferon alfa-2a + ribavirin) PegIntron + Rebetol (peginterferon alfa-2b + ribavirin) Roferon A + Ribavirin (Standard interferon alfa-2a + ribavirin) Intron A + Rebetol (Standard Interferon alfa-2b + ribavirin) Infergen + Ribavirin (consensus Interferon + ribavirin)
Boceprevir + Pegylated Interferon + Ribavirin
Articles on Boceprevir + Pegylated Interferon + Ribavirin
Boceprevir Patient Assistance Programs 5-31-2011 Boceprevir (Victrelis) Approved for Hepatitis C 5-17-2011 Boceprevir for HCV Wins Unanimous FDA Committee Recommendation 4-29-2011 FDA Hearings Next Week on Boceprevir and Telaprevir for HCV 4-23-2011 Boceprevir Improves Response to Interferon-Based HCV Therapy 4-1-2011 FDA Committee Sets Review Dates for HCV Drugs Boceprevir and Telaprevir 3-18-2011 HCV Protease Inhibitor Boceprevir Improves Response for Treatment-Naive and Non-responders 3-15-2011 HCV Protease Inhibitor Boceprevir Accepted for Priority Review in U.S. and Europe 1-14-2010 Boceprevir Improves Response to Interferon-based Therapy and Allows Many Patients to Reduce Duration 11/02/2010 HCV RESPOND-2 Final Results High Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin when Re- Treated with Boceprevir Plus PEGINTRON (Peginterferon alfa-2b)/Ribavirin 11/02/2010 Boceprevir Combined with Peginterferon alfa-2b/Ribavirin for Treatment-Naïve Patients with HCV Genotype 1 11/02/2010 HCV Protease Inhibitor Boceprevir Increased Sustained Response to Interferon-based Therapy in Phase 3 Studies 8/06/2010
Telaprevir + Pegylated Interferon + Ribavirin
Articles on Telaprevir + Pegylated Interferon + Ribavirin
Telaprevir Improves Hepatitis C Treatment Response 6-28-2011 Telaprevir Patient Assistance Programs 5-31-2011 Telaprevir (Incivek) Approved for Hepatitis C 5-24-2011 FDA Committee Unanimously Recommends Telaprevir 5-03-2011 FDA Hearings Next Week on Boceprevir and Telaprevir for HCV 4-23-2011 Telaprevir Improves HCV Cure Rates Regardless of IL28B Status 4-5-2011
Telaprevir Combo Works for HCV Patients with Prior Unsuccessful Treatment 4-1-2011 FDA Committee Sets Review Dates for HCV Drugs Boceprevir and Telaprevir 3-18-2011 HCV Protease Inhibitor Telaprevir Will Get Priority Review in U.S. and Canada 1-25-2011 Vertex Completes FDA Submission of Telaprevir New Drug Application 11/30/2010 Direct-acting Drug Combos Suppress HCV without Interferon, but Resistance Remains a Concern 11/15/2010 Telaprevir Increases Sustained Response Rates and Shortens Treatment Duration for Newly Treated Hepatitis C Patients 11/02/2010 Vertex Begins Trial of Telaprevir for Treatment-naive Chronic Hepatitis C Patients 10/29/2010 Telaprevir Combination Therapy Boosts Sustained Response Rates for Previously Treated Hepatitis C Patients 9/10/2010
Pegasys + Copegus peginterferon alfa-2a + Copegus (ribavirin)
Articles on Pegasys + Copegus
PegIntron + Rebetol peginterferon alfa-2b + Rebetol (ribavirin)
Intron A + Rebetol (interferon alfa-2b + ribavirin)
Articles on Intron A + Rebetol
Roferon A + Ribavirin (interferon alfa-2a + ribavirin)
Articles on Roferon A + Ribavirin
Asian Patients Respond as Well as Whites to Interferon-based Therapy for Chronic Hepatitis C 7-13-2010 Interferon-based Therapy Less Effective for Hepatitis C Patients with Advanced Liver Fibrosis or Cirrhosis 4-9-2010 Can Some Genotype 1 Chronic Hepatitis C Patients Benefit from Shorter Interferon-based Treatment? 2/16/2010 Management of Depression During Hepatitis C Treatment with Interferon-based Therapy 1/29/2010 Influence of HCV Subtype and Quasispecies on Virological Response to Interferon-Based Therapy 1/12/2010 Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy 12/01/09 Sustained Virological Response to Interferon-based Therapy Slows Progression of Liver Cirrhosis in Hepatitis C Patients 11/24/09 HCV Viral Load Decline during the First 24 Hours of Interferon-based Therapy Predicts Long-term Outcomes in HIV-HCV Coinfected Patients 9-18-2009 FDA Requires Updated Labeling for Interferon Alpha Products Due to Recently Identified Safety Issues 9-04-2009 Increases in ALT Late in the Course of Interferon-based Therapy for Chronic Hepatitis C Predicts Relapse 7-17-2009 Interferon-based Therapy Reduces or Reverses Liver Fibrosis over the Long-term in Chronic Hepatitis C Patients 7-07-2009 Early Bilirubin Elevation May Predict Severe Anemia during Interferon/ribavirin Treatment for Chronic Hepatitis C 7-07-2009 Interferon-based Therapy for Hepatitis C Improves Fibrosis Even in Individuals without Virological Response 4/21/09 Sustained Response to Interferon-based Therapy Reduces Risk of Diabetes in Hepatitis C Patients 4/21/09 A Small Proportion of Hepatitis C Patients Develop Liver Cancer despite Sustained Response to Interferon-based Therapy 4/13/09 Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C 4/03/09
Infergen + Ribavirin (Consensus Interferon + Ribavirin)
Articles on Infergen + Ribavirin Consensus Interferon (Infergen) Label Changed to Include Data on Dosing with Ribavirin 7/09/2010
Cirrhosis Fibrosis Hepatocellular Carcinoma Liver Transplantation Liver Biopsy Steatosis Anemia Children / Infants / Women Drug Abuse Experimental Treatments FAQs About Hepatitis C Genotypes Insulin Resistance / Diabetes Sustained Viral Response (SVR) Tests for HCV Vaccines for HCV
Articles on Boceprevir + Pegylated Interferon + Ribavirin
